DUBLIN--(BUSINESS WIRE)--The "Menopausal Disorders Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.
This report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for postmenopausal osteoporosis, vaginal atrophy and vasomotor symptoms of menopause, and features dormant and discontinued products.
Postmenopausal osteoporosis is the most common form of osteoporosis. There are 20 products in development for this indication.
Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to the body having less estrogen. There are five products in development for this indication.
Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. There are 12 products in development for this indication.
Molecular targets acted on by products in development for menopausal disorders include tumor necrosis factor ligand superfamily member 11, parathyroid hormone receptor and progesterone receptor. Companies operating in this pipeline space include Amgen, TherapeuticsMD and Ipsen.
Companies Featured
- Amgen Inc
- EndoCeutics Inc
- Enteris BioPharma Inc
- GL Pharm Tech Corp
- Intas Pharmaceuticals Ltd
- Ipsen SA
- Ligand Pharmaceuticals Inc
- Lupin Ltd
- Luye Pharma Group Ltd
- Medinova AG
- MenoGeniX Inc
- Mithra Pharmaceuticals SA
- NIBEC
- Ogeda SA
- Oncobiologics Inc
- Paras Biopharmaceuticals Finland Oy
- Pherin Pharmaceuticals Inc
- TherapeuticsMD Inc
- Uni-Bio Science Group Ltd
Key Topics Covered
1 Table of Contents
2 Introduction
3 Therapeutics Development
4 Therapeutics Assessment
5 Companies Involved in Therapeutics Development
6 Dormant Projects
7 Discontinued Products
8 Product Development Milestones
9 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/xs2lrv/menopausal?w=4
